ArticleFrontiers in genetics2025
Identification of key genes for heart failure in dilated cardiomyopathy in different populations.
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Genetic Overlap Between Dilated Cardiomyopathy and Neurological Disorders: Insights from a Next-Generation Sequencing Study.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Heart failure (HF) represents the end stage of cardiovascular disease and is the leading cause of mortality. The objective of this study was to identify potential biomarkers and elucidate the mechanisms underlying the development of HF across diverse populations and among different genders. Methods: This study strictly included five datasets of HF with dilated cardiomyopathy: GSE141910 (African American and Caucasian), GSE57345 (USA), GSE21610 (Germany), GSE17800 (Germany), and GSE42955 (Spain). These datasets were merged and normalized as the validation set. Differentially expressed genes (DEGs) were identified through differential expression analysis, and module genes were identified using weighted gene co-expression network analysis. Subsequent stratification by gender and ethnicity (African American, Caucasian, German, and Spanish) was performed, followed by immune infiltration analysis. Finally, the least absolute shrinkage and selection operator (LASSO) regression, support vector machine-recursive feature elimination (SVM-REF), and random forest (RF) models were used to screen for Hub genes and to construct a nomogram predicting the occurrence of HF in different populations based on these Hub genes. Additionally, GSE3585, GSE120895, GSE5406, and GSE1145 serve as the validation set. Results: A total of 650 samples were included (323 controls and 327 HF samples), including 122 African American samples (44 controls and 78 HF samples), 238 Caucasian samples (122 controls and 116 HF samples), 55 German samples (16 controls and 39 HF samples), and 17 Spanish samples (5 controls and 12 HF samples). Functional enrichment analysis demonstrated that the pathogenesis of HF is closely related to the inflammatory response, immune response, vascular regulation, the Wnt signaling pathway, glutathione metabolism, sphingolipid metabolism, and apoptosis. Immune infiltration analysis showed that HF patients exhibited a high abundance of resting mast cells, resting NK cells, CD8T cells, resting memory CD4 T cells, activated memory CD4 T cells, M1 Macrophages, naive CD4 T cells, M0 Macrophages, regulatory T cells (Tregs), follicular helper T cells, Monocytes, and activated NK cells, and a lower abundance of plasma cells, neutrophils, and eosinophils. Multiple machine learning analyses identified MYH6, ASPN, and COL14A1 as Hub genes, NAP1L3, PLEKHH2, MOXD1, CCDC80, CA14, and SERPINE2 as male-specific, CX3CR1, SYN2, and SLC25A18 as female-specific, and NQO1, KAZALD1, and UBASH3A as African American male-specific, SYN2 as African American female-specific, CD83, C1QTNF3, GRB14, and MOXD1 as Caucasian male-specific, CD83, VIT, and PODXL2 as Caucasian female-specific, LSAMP and C14orf132 as German male-specific, and LSAMP and BMP4 as German female-specific, CIART and SNORA80E as Spanish-specific DEGs. Hub genes are strongly associated with M1 macrophages. Conclusion: The biomarkers of HF vary significantly across different populations and genders. MYH6, ASPN, and COL14A1 may be potential biomarkers for HF in dilated cardiomyopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.